An article just published in the August 2023 issue of
The Lancet Oncology can be expected to create
considerable discussion. The article reports the preliminary
findings of a large prospective study in Sweden that has
essentially found equivalency of use of AI by a single radiologist
in diagnosing screening mammography studies when compared to double
readings of mammograms by two diagnostic radiologists, reducing the
manpower required by almost half.
This is the first randomized trial ever conducted where the
clinical safety of an AI-supported mammography screen-reading
protocol used by a single radiologist was compared with
interpretations of mammography studies performed by two
radiologists. The results are significant.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.